Neoleukin Therapeutics, Inc. - FORM S-1/A - EX-23.1 - CONSENT OF DELOITTE LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - February 28, 2014

Attached files

file filename
S-1/A - S-1/A - Neoleukin Therapeutics, Inc.d619679ds1a.htm
EX-10.12 - ASSET PURCHASE AGREEMENT - Neoleukin Therapeutics, Inc.d619679dex1012.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - Neoleukin Therapeutics, Inc.d619679dex11.htm
EX-5.1 - OPINION OF COOLEY LLP REGARDING LEGALITY. - Neoleukin Therapeutics, Inc.d619679dex51.htm
EX-3.3 - CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Neoleukin Therapeutics, Inc.d619679dex33.htm
EX-10.16 - CONSENT TO SUBLEASE - Neoleukin Therapeutics, Inc.d619679dex1016.htm
EX-3.5 - FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Neoleukin Therapeutics, Inc.d619679dex35.htm
EX-3.6 - FORM OF AMENDED AND RESTATED BYLAWS OF THE REGISTRANT - Neoleukin Therapeutics, Inc.d619679dex36.htm

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Amendment No. 1 to Registration Statement on Form S-1 No. 333-193615 of our report dated January 28, 2014 (except for Note 16, as to which the date is February 27, 2014) relating to the combined financial statements of Aquinox Pharmaceuticals, Inc. (formerly known as Aquinox Pharmaceuticals (USA) Inc.) and Aquinox Pharmaceuticals Inc. (which report expresses an unmodified opinion and includes an emphasis-of-matter paragraph relating to the Companies being a development stage enterprise) appearing in the Prospectus, which is a part of this Registration Statement, and to the reference to us under the heading “Experts” in such Prospectus.

/s/ Deloitte LLP

Chartered Accountants

Vancouver, Canada

February 28, 2014

Neoleukin Therapeutics, Inc. Reports